펩티드 합성 시장(제3판) : 동향과 예측(-2035년)원료의약품(API) 유형별, 펩티드 합성법 유형별, 화학 합성법 유형별, 사업 규모별, 기업 규모별, 지역별

Peptide Synthesis Market: Overview

As per Roots Analysis, the peptide synthesis market is estimated to grow from USD 4.2 billion in the current year to USD 6.0 billion by 2035, at a CAGR of 4.1% during the forecast period, till 2035.

Peptide Synthesis Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of API

• Generic APIs
• New Chemical Entities

By Type of Peptide Synthesis Method

• Chemical Synthesis
• Non-Chemical Synthesis

By Type of Chemical Synthesis Method

• Solid Phase Synthesis
• Liquid Phase Synthesis
• Hybrid Phase Synthesis

By Scale of Operation

• Commercial Scale
• Preclinical / Clinical Scale

By Company Size

• Small Companies
• Mid-sized Companies
• Large and Very Large Companies

By Geographical Regions

• North America
• US
• Canada
• Europe
• Belgium
• Switzerland
• UK
• Germany
• Ireland
• Netherlands
• Italy
• France
• Sweden
• Rest of Europe

Asia-Pacific and Rest of the World

• China
• India
• Japan
• Korea
• Rest of Asia-Pacific and Other Countries

Peptide Synthesis Market: Growth and Trends

Over the years, peptides have gained significance as therapeutic candidates due to their improved metabolic stability, specificity for biological targets, and greater affinity. In this time frame, the peptide production field has advanced considerably with the increasing demand for peptide-based therapies. At present, regulatory bodies in various parts of the world have authorized approximately 100 peptide therapeutics to address a wide range of chronic conditions, such as cancer, chronic pain, diabetes, HIV infection, multiple sclerosis, and osteoporosis. The increasing research efforts in this area and rising demand for such therapeutic options have led developers to enhance their capabilities and improve the production machinery. Nonetheless, the peptide synthesis process faces numerous challenges, such as a lack of production capacity. Consequently, developers are progressively delegating intricate manufacturing tasks to expert contract service providers, allowing for cost savings and quicker market entry

Growth Drivers: Strategic Enablers of Market Expansion

The peptide synthesis market has experienced robust growth and technological breakthroughs, driven by demand for peptide-based therapeutics, diagnostics, and research tools. Key advancements include automation, AI integration, and greener chemistry, enhancing efficiency and scalability. Further, the increasing global prevalence of chronic diseases, such as cancer and metabolic disorders, has intensified the demand for more targeted and effective peptide-based therapies. This growing therapeutic need fuels a larger and more complex R&D pipeline, resulting in drug developers outsourcing API production to specialized CDMOs for clinical and commercial supply.

Market Challenges: Critical Barriers Impeding Progress

The peptide synthesis market faces significant hurdles that hinder its growth despite strong demand for therapeutics and research applications. Key challenges include high production costs, scalability issues, and stringent regulations, which particularly impact smaller players and complex peptide development. Further, stringent GMP / ICH compliance, validation, and quality controls prolong timelines and raise costs, posing entry barriers for new entrants. Immunogenicity risks require extensive testing and redesigns, while unsustainable solvents and waste challenge greener processes amid supply chain vulnerabilities.

Peptide Synthesis Market: Key Insights

The report delves into the current state of the peptide synthesis market and identifies potential growth opportunities within industry. Some key findings from the report include:

• The current market landscape features a presence of around 95 companies that claim to have the required capabilities to offer contract manufacturing for peptide APIs, worldwide.

• Close to 70% players engaged in this domain offer contract manufacturing services for generic APIs; further, ~20% claim to have the required capabilities to manufacture peptides using all three chemical synthesis methods.
• Over 35% of the deals inked in this domain were acquisitions; majority of the intracontinental deals were signed by players based in Europe.
• As demand for peptide therapeutics accelerates, companies are strategically investing to scale-up capacity and strengthen their capabilities; this trend is most prominently observed across Asia-Pacific region.

• Clinical trials investigating various peptide therapeutics are well distributed across several geographical regions; maximum patient enrollment (with 86,608 patients) was observed in North America.
• Players are actively making efforts to increase their production capacities to meet the growing demand for peptide-based drugs; the rising interest of developers in peptides is evident from the increase in clinical studies.
• Given the growing complexity of peptide APIs, the demand for outsourcing has upsurged; by 2035, it is anticipated to reach over 4,400 kilograms, across clinical and commercial scales.
• The global, installed peptide API contract manufacturing capacity is spread across various geographies; interestingly, over 90% of the total capacity is installed at the facilities owned by large and very large players.
• Various peptide therapeutic developers are anticipated to forge strategic alliances with peptide API contract manufacturing service providers in order to outsource complex manufacturing operations.
• The regulatory frameworks established for peptide API manufacturing vary across countries, upholding a common goal of protecting public health, ensuring product quality, and minimizing associated risks.
• Driven by the increasing number of chronic indications (requiring novel personalized therapies), and ongoing research on peptide-based therapeutics, this market is anticipated to grow at a steady rate.
• Close to 50% of the market is anticipated to be captured by revenues generated from solid phase synthesis; the peptide API contract manufacturing market for small companies is likely to grow at a faster pace.

• The US peptide API contract manufacturing market is projected to grow at a decent pace, driven by rising prevalence of chronic diseases and increasing peptide API outsourcing to specialized CMOs.
• The US peptide API contract manufacturing market, supported by a robust pharmaceutical manufacturing base and a favorable regulatory environment, is projected to reach USD 1.8 billion by 2035.

Peptide Synthesis Market: Key Segments

Solid Phase Synthesis to be the Cornerstone of Peptide Synthesis

In terms of the type of chemical synthesis method, the global market is segmented into solid phase synthesis, liquid phase synthesis, and hybrid phase synthesis. The peptide synthesis market report indicates that the solid phase synthesis method segment accounts for 49% of the total market share, in the current year. This dominance arises from the many benefits of the solid phase synthesis method, such as fast generation of linear peptides, easier purification, and affordability. It is crucial to emphasize that the hybrid phase synthesis segment is expected to experience a greater CAGR. This expansion is mainly due to its distinct appropriateness for the intricate and lengthy peptide sequences entering the R&D pipeline. This method utilizes the advantages of both SPPS and LPPS, providing the best efficiency, yield, and cost-effectiveness for next-generation therapeutics that are challenging to produce with just one technique.

Commercial Scale Manufacturing to Retain Dominant Share

In terms of the different scales of operation, the global market is segmented into commercial scale, and preclinical / clinical scale. The peptide synthesis market prediction suggests that the commercial scale sector represents more than 90% of the total market share. It is worth highlighting that the commercial scale segment will lead in the future and is expected to expand at a greater CAGR. The significant peptide synthesis market size primarily results from the large volumes and high financial value linked to producing GMP-grade peptide APIs. Long-term supply contracts for marketed therapies create revenue generation opportunities that greatly exceed that of preclinical and clinical scale projects.

Europe Dominates the Market for Peptide Synthesis

Our analysis of the peptide synthesis market indicates that Europe is leading by capturing 40% of the total revenue share. This dominance is probably due to the substantial portion of global manufacturing capacity in the region, an increased number of clinical trials conducted there, and a solid innovation ecosystem supported by strong partnerships between academia and industry.

Primary Research Overview

The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Founder and Owner, Small Company, Germany
• Chief Financial Officer, Small Company, Germany
• Chief Business Officer, Small Company, US
• Senior Director of Scientific Affairs and Technical Marketing, Small Company, US
• Vice President, Peptides, Large Company, Ireland
• Senior Manager, Peptide Business Project Leader, Large Company, Japan
• Chief Scientific Officer, Co-Founder, Small Company, India

Example Players in Peptide Synthesis Market

• AmbioPharm
• Creative Peptides
• CSBio
• Bachem
• BCN Peptides
• CordenPharma
• PolyPeptide
• Senn Chemicals
• Auspep
• Hybio Pharmaceuticals
• Peptide Institute
• ScinoPharm

Peptide Synthesis Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the peptide synthesis market, focusing on key market segments, including [A] type of API, [B] type of peptide synthesis method, [C] type of chemical synthesis method, [D] scale of operation, [E] company size, and [F] geographical regions.
• Market Landscape: A detailed overview of the current market landscape of contract manufacturers offering peptide therapeutics contract API manufacturing services, along with information on several relevant parameters, such as [A] year of establishment, [B] year of experience of peptide API contract manufacturers, [C] company size, [D] location of headquarters, [E] type of product, [F] type of API manufactured, [G] scale of operation, [H] type of service offered, [I] type of peptide synthesis method, [J] type of chemical peptide synthesis method, [K] type of peptide modification offered, [L] type of purification techniques used, [M] regulatory certifications and accreditations, [N] geographical presence and [O] location of peptide API manufacturing facilities.
• Company Competitiveness Analysis: An insightful company competitiveness analysis of prominent contract manufacturers in the peptide API contract manufacturing industry, based on several relevant parameters, such as [A] supplier strength, [B] service portfolio and [A] number of peptide modification services offered.
• Company Profiles: In-depth profiles of prominent players North America, Europe and Asia-Pacific that are engaged in the peptide therapeutics manufacturing market based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
• Recent Developments: An analysis on the recent developments and initiatives undertaken by contract manufacturers within the peptide API contract manufacturing industry, highlighting information on several partnerships and collaborations and expansions initiatives that have been inked during the last five years.
• Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical studies of various peptide therapeutics, based on various relevant parameters, such as [A] trial registration year, [A] number of patients enrolled, [B] patient gender, [C] trial phase, [D] trial status, [E] therapeutic area, [F] type of sponsor / collaborator, [G] study design, [H] most active players (in terms of number of clinical trials), and [I] geography.
• Regional Capability Analysis: An analysis of peptide API contract manufacturers capabilities in different regions, based on several relevant parameters, such as [A] number of CMOs, [B] number of clinical sites, [C] number of clinical trials, [D] number of patients enrolled, [E] number of peptide manufacturing facilities, [F] type of product, [G] number of clinical / commercial manufacturing CMOs, [H] demand for peptide therapeutics and [I] installed capacity.
• Demand Analysis: A detailed analysis of the annual commercial and clinical demand for peptide therapeutics, based on several relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dosage strength.
• Capacity Analysis: An estimate of the global, installed capacity of contract manufacturers in the peptide API contract manufacturing market, taking into consideration the distribution of available peptide production capacity across [A] companies of different sizes, [B] scale of operation, and [C] location of manufacturing facility.
• Likely Partners Analysis: An analysis highlighting potential strategic partners segregated based on the likelihood of entering into collaboration with peptide therapeutics developers.
• Make Versus Buy Decision Making Framework: A qualitative analysis highlighting various factors that need to be taken into consideration by peptide drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
• Total Cost of Ownership: A detailed analysis of the total cost of ownership for a peptide contract manufacturing service provider. It features an informed estimate of direct and indirect expenses taking into consideration 10 relevant parameters, over a span of 20 years.
• SWOT Analysis: A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.

Key Questions Answered in this Report

• Which are the leading companies in peptide synthesis market?
• Which region dominates the peptide synthesis market?
• What are the key trends observed in the peptide synthesis market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by peptide synthesis manufacturers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complementary PPT Insights Pack
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Value and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product (GDP)
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross-Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
  • 5.2.1. Recent Developments
  • 5.2.2. Clinical Trial Analysis
  • 5.2.3. Demand and Capacity Analysis
  • 5.2.4. Total Cost of Ownership
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Overview of Peptides
  • 6.2.1. Structural Analysis of Peptides
  • 6.2.2. Classification of Peptides
  • 6.2.3. Peptide Synthesis
  • 6.2.4. Emerging Technologies for Peptide Synthesis
  • 6.2.5. Peptide Modification
    • 6.2.5.1. N-terminal Modifications
    • 6.2.5.2. Internal Modifications
    • 6.2.5.3. C-terminal Modifications
    • 6.2.5.4. Other Modifications
  • 6.2.6. Peptide Purification
  • 6.2.7. Peptide Purity Guidelines
• 6.3. Overview of Contract Manufacturing
  • 6.3.1. Need for Outsourcing in the Peptide Manufacturing Industry
  • 6.3.2. General Considerations for Selecting a CMO Partner
  • 6.3.3. Advantages of Outsourcing Manufacturing Operations
  • 6.3.4. Risks and Challenges Associated with Outsourcing of Peptide API Manufacturing
• 6.4. Future Perspectives

7. REGULATORY LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Regulatory Scenario: North America
  • 7.2.1. Scenario in the US
    • 7.2.1.1. Overview
    • 7.2.1.2. General Guidelines for Peptide Manufacturing
• 7.3. Regulatory Scenario: Europe
  • 7.3.1. Scenario in Europe
    • 7.3.1.1. Overview
    • 7.3.1.2. General Guidelines
  • 7.3.2. Scenario in the UK
    • 7.3.2.1. Overview
    • 7.3.2.2. General Guidelines for Peptide Manufacturing
• 7.4. Regulatory Scenario: Asia-Pacific
  • 7.4.1. Overview
  • 7.4.2. Scenario in Australia
    • 7.4.2.1. General Guidelines for Peptide Manufacturing
  • 7.4.3. Scenario in China
    • 7.4.3.1. General Guidelines for Peptide Manufacturing
    • 7.4.3.2. Tax-related Modifications in
  • 7.4.4. Scenario in India
    • 7.4.4.1. General Guidelines for Peptide Manufacturing
    • 7.4.4.2. Tax-related Modifications in
  • 7.4.5. Scenario in Japan
    • 7.4.5.1. General Guidelines for Peptide Manufacturing
  • 7.4.6. Scenario in South Korea
    • 7.4.6.1. General Guidelines for Peptide Manufacturing
• 7.5. Challenges Associated with Peptide Manufacturing

8. MARKET LANDSCAPE

• 8.1. Chapter Overview
• 8.2. Peptide API Contract Manufacturing: Overall Market Landscape
  • 8.2.1. Analysis by Year of Establishment
  • 8.2.2. Analysis by Year of Experience of Peptide API Contract Manufacturers
  • 8.2.3. Analysis by Company Size
  • 8.2.4. Analysis by Location of Headquarters
  • 8.2.5. Analysis by Type of Product Manufactured
  • 8.2.6. Analysis by Type of API Manufactured
  • 8.2.7. Analysis by Scale of Operation
  • 8.2.8. Analysis by Type of Service Offered
  • 8.2.9. Analysis by Type of Peptide Synthesis Method Used
  • 8.2.10. Analysis by Type of Peptide Modification Offered
  • 8.2.11. Analysis by Type of Purification Technology Used
  • 8.2.12. Analysis by Regulatory Certifications and Accreditations
  • 8.2.13. Analysis by Geographical Presence
  • 8.2.14. Analysis by Location of Peptide API Manufacturing Facilities
• 8.3. List of Custom Peptide Manufacturers

9. COMPANY COMPETITIVENSS ANALYSIS

• 9.1. Chapter Overview
• 9.2. Key Parameters
• 9.3. Methodology
• 9.4. Company Competitiveness Analysis
  • 9.4.1. Peptide API Contract Manufacturers Headquartered in North America
  • 9.4.2. Peptide API Contract Manufacturers Headquartered in Europe
  • 9.4.3. Peptide API Contract Manufacturers Headquartered in Asia-Pacific and Rest of the World

10. COMPANY PROFILES: PEPTIDE API CONTRACT MANUFACTURERS

• 10.1. Chapter Overview
• 10.2. Peptide API Contract Manufacturers based in North America
  • 10.2.1. AmbioPharm
    • 10.2.1.1. Company Overview
    • 10.2.1.2. Peptide Synthesis Service Portfolio
    • 10.2.1.3. Peptide API Manufacturing Facilities and Capabilities
    • 10.2.1.4. Recent Developments and Future Outlook
  • 10.2.2. Creative Peptides
    • 10.2.2.1. Company Overview
    • 10.2.2.2. Peptide Synthesis Service Portfolio
    • 10.2.2.3. Peptide API Manufacturing Facilities and Capabilities
    • 10.2.2.4. Recent Developments and Future Outlook
  • 10.2.3. CSBio
    • 10.2.3.1. Company Overview
    • 10.2.3.2. Peptide Synthesis Service Portfolio
    • 10.2.3.3. Peptide API Manufacturing Facilities and Capabilities
    • 10.2.3.4. Recent Developments and Future Outlook
• 10.3. Peptide API Contract Manufacturers based in Europe
  • 10.3.1. Bachem
    • 10.3.1.1. Company Overview
    • 10.3.1.2. Financial Information
    • 10.3.1.3. Peptide Synthesis Service Portfolio
    • 10.3.1.4. Peptide API Manufacturing Facilities and Capabilities
    • 10.3.1.5. Recent Developments and Future Outlook
  • 10.3.2. BCN Peptides
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Peptide Synthesis Service Portfolio
    • 10.3.2.3. Peptide API Manufacturing Facilities and Capabilities
    • 10.3.2.4. Recent Development and Future Outlook
  • 10.3.3. CordenPharma
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Peptide Synthesis Service Portfolio
    • 10.3.3.3. Peptide API Manufacturing Facilities and Capabilities
    • 10.3.3.4. Recent Developments and Future Outlook
  • 10.3.4. PolyPeptide
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Information
    • 10.3.4.3. Peptide Synthesis Service Portfolio
    • 10.3.4.4. Peptide API Manufacturing Facilities and Capabilities
    • 10.3.4.5. Recent Developments and Future Outlook
  • 10.3.5. Senn Chemicals
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Peptide Synthesis Service Portfolio
    • 10.3.5.3. Peptide API Manufacturing Facilities and Capabilities
    • 10.3.5.4. Recent Developments and Future Outlook
• 10.4. Peptide API Contract Manufacturers based in Asia-Pacific
  • 10.4.1. Auspep
    • 10.4.1.1. Company Overview
    • 10.4.1.2. Peptide Synthesis Service Portfolio
    • 10.4.1.3. Peptide API Manufacturing Facilities and Capabilities
    • 10.4.1.4. Recent Developments and Future Outlook
  • 10.4.2. Hybio Pharmaceutical
    • 10.4.2.1. Company Overview
    • 10.4.2.2. Peptide Synthesis Service Portfolio
    • 10.4.2.3. Peptide API Manufacturing Facilities and Capabilities
    • 10.4.2.4. Recent Developments and Future Outlook
  • 10.4.3. Peptide Institute
    • 10.4.3.1. Company Overview
    • 10.4.3.2. Peptide Synthesis Service Portfolio
    • 10.4.3.3. Peptide API Manufacturing Facilities and Capabilities
    • 10.4.3.4. Recent Developments and Future Outlook
  • 10.4.4. ScinoPharm
    • 10.4.4.1. Company Overview
    • 10.4.4.2. Financial Information
    • 10.4.4.3. Peptide Synthesis Service Portfolio
    • 10.4.4.4. Peptide API Manufacturing Facilities and Capabilities
    • 10.4.4.5. Recent Developments and Future Outlook
• 10.5. Company Deep Dive: Peptide API Contract Manufacturers
  • 10.5.1. Amneal Pharmaceuticals
    • 10.5.1.1. Company Details
    • 10.5.1.2. Financial Details
    • 10.5.1.3. SWOT Analysis
    • 10.5.1.4. Strategic Framework
    • 10.5.1.5. Recent Developments and Future Outlook
  • 10.5.2. Asymchem
    • 10.5.2.1. Company Details
    • 10.5.2.2. Peptide Synthesis Service Portfolio
    • 10.5.2.3. Peptide Synthesis Facilities
    • 10.5.2.4. Financial Details
    • 10.5.2.5. SWOT Analysis
    • 10.5.2.6. Strategic Framework
    • 10.5.2.7. Recent Developments and Future Outlook
  • 10.5.3. Aurisco Pharma
    • 10.5.3.1. Company Details
    • 10.5.3.2. Peptide Synthesis Facilities
    • 10.5.3.3. Financial Details
    • 10.5.3.4. SWOT Analysis
    • 10.5.3.5. Strategic Framework
    • 10.5.3.6. Recent Developments and Future Outlook
  • 10.5.4. Dr Reddy's Laboratories
    • 10.5.4.1. Company Details
    • 10.5.4.2. Peptide Synthesis Service Portfolio
    • 10.5.4.3. Peptide Synthesis Facilities
    • 10.5.4.4. Financial Details
    • 10.5.4.5. SWOT Analysis
    • 10.5.4.6. Strategic Framework
    • 10.5.4.7. Recent Developments and Future Outlook
  • 10.5.5. Hybio Pharmaceutical
    • 10.5.5.1. Company Details
    • 10.5.5.2. Peptide Synthesis Service Portfolio
    • 10.5.5.3. Peptide Synthesis Facilities
    • 10.5.5.4. SWOT Analysis
    • 10.5.5.5. Strategic Framework
    • 10.5.5.6. Recent Developments and Future Outlook
  • 10.5.6. JYMed Peptide
    • 10.5.6.1. Company Details
    • 10.5.6.2. Peptide Synthesis Service Portfolio
    • 10.5.6.3. Peptide Synthesis Facilities
    • 10.5.6.4. SWOT Analysis
    • 10.5.6.5. Strategic Framework
    • 10.5.6.6. Recent Developments and Future Outlook
  • 10.5.7. Neuland Labs
    • 10.5.7.1. Company Details
    • 10.5.7.2. Peptide Synthesis Service Portfolio
    • 10.5.7.3. Peptide Synthesis Facilities
    • 10.5.7.4. Financial Details
    • 10.5.7.5. SWOT Analysis
    • 10.5.7.6. Strategic Framework
    • 10.5.7.7. Recent Developments and Future Outlook
  • 10.5.8. Sinopep-Allsino Biopharmaceutical
    • 10.5.8.1. Company Details
    • 10.5.8.2. Peptide Synthesis Service Portfolio
    • 10.5.8.3. Peptide Synthesis Facilities
    • 10.5.8.4. Financial Details
    • 10.5.8.5. SWOT Analysis
    • 10.5.8.6. Strategic Framework
    • 10.5.8.7. Recent Developments and Future Outlook
  • 10.5.9. SK Pharmteco
    • 10.5.9.1. Company Details
    • 10.5.9.2. Financial Details
    • 10.5.9.3. SWOT Analysis
    • 10.5.9.4. Strategic Framework
    • 10.5.9.5. Recent Developments and Future Outlook
  • 10.5.10. WuXi STA (a WuXi AppTec company)
    • 10.5.10.1. Company Details
    • 10.5.10.2. Peptide Synthesis Service Portfolio
    • 10.5.10.3. Peptide Synthesis Facilities
    • 10.5.10.4. Financial Details
    • 10.5.10.5. SWOT Analysis
    • 10.5.10.6. Strategic Framework
    • 10.5.10.7. Recent Developments and Future Outlook

11. RECENT DEVELOPMENTS

• 11.1. Chapter Overview
• 11.2. Partnerships and Collaborations
  • 11.2.1. Partnerships Models
  • 11.2.2. List of Partnerships and Collaborations
  • 11.2.3. Analysis by Year of Partnership
  • 11.2.4. Analysis by Type of Partnership
  • 11.2.5. Analysis by Year and Type of Partnership
  • 11.2.6. Analysis by Company Size and Type of Partnership
  • 11.2.7. Analysis by Scale of Operation
  • 11.2.8. Analysis by Scale of Operation and Type of Partnership
  • 11.2.9. Analysis by Green Chemistry Integration
  • 11.2.10. Most Active Players: Analysis by Number of Partnerships
  • 11.2.11. Analysis by Geography
    • 11.2.11.1. Intercontinental and Intracontinental Agreements
    • 11.2.11.2. Local and International Agreements
• 11.3. Recent Expansions
  • 11.3.1. Expansion Models
  • 11.3.2. List of Recent Expansions
  • 11.3.3. Analysis by Year of Expansion
  • 11.3.4. Analysis by Type of Expansion
  • 11.3.5. Analysis by Year and Type of Expansion
  • 11.3.6. Analysis by Location of Expanded Facility (Region)
  • 11.3.7. Analysis by Location of Expanded Facility (Country)
  • 11.3.8. Recent Expansions: Analysis by Location of Expanded Facility and Type of Expansion
  • 11.3.9. Most Active Players: Analysis by Number of Expansions
  • 11.3.10. Recent Expansions: Analysis by Geography (Country)
• 11.4. Emerging Peptide Synthesis Technologies
  • 11.4.1. Chemo-Enzymatic Peptide Synthesis Technology
  • 11.4.2. Continuous Flow Technology
  • 11.4.3. Green Chemistry

12. CLINICAL TRIAL ANALYSIS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Peptide Therapeutics: Clinical Trials Analysis
  • 12.3.1. Analysis by Trial Registration Year
  • 12.3.2. Analysis by Number of Patients Enrolled by Trial Registration Year
  • 12.3.3. Analysis by Trial Phase
  • 12.3.4. Analysis of Trials by Trial Registration Year and Trial Phase
  • 12.3.5. Analysis by Number of Patients Enrolled by Trial Phase
  • 12.3.6. Analysis by Trial Status
  • 12.3.7. Analysis by Trial Registration Year and Trial Status
  • 12.3.8. Analysis by Therapeutic Area
  • 12.3.9. Analysis by Patient Gender
  • 12.3.10. Analysis by Type of Sponsor / Collaborator
  • 12.3.11. Analysis by Study Design
    • 12.3.11.1. Analysis by Type of Allocation
    • 12.3.11.2. Analysis by Type of Masking
    • 12.3.11.3. Analysis by Type of Intervention
    • 12.3.11.4. Analysis by Trial Purpose
  • 12.3.12. Leading Industry Players: Analysis by Number of Clinical Trials
  • 12.3.13. Analysis by Geography
    • 12.3.13.1. Analysis of Clinical Trials by Geography
    • 12.3.13.2. Analysis of Clinical Trials by Geography and Trial Status
    • 12.3.13.3. Analysis of Patients Enrolled by Geography
    • 12.3.13.4. Analysis of Patients Enrolled by Geography and Trial Status

13. REGIONAL CAPABILITY ANALYSIS

• 13.1. Chapter Overview
• 13.2. Key Assumptions and Methodology
• 13.3. Overall Landscape of Peptide API Contract Manufacturing Facilities
• 13.4. Peptide API Contract Manufacturing Capability in North America
• 13.5. Peptide API Contract Manufacturing Capability in Europe
• 13.6. Peptide API Contract Manufacturing Capability in Asia-Pacific and Rest of the World

14. DEMAND ANALYSIS

• 14.1. Chapter Overview
• 14.2. Assumptions and Methodology
• 14.3. Peptide API Contract Manufacturing: Annual Global Demand
  • 14.3.1. Peptide API Contract Manufacturing: Annual Clinical Demand
    • 14.3.1.1. Clinical Demand for Peptide API Contract Manufacturing: Analysis by Phase of Development
  • 14.3.2. Peptide API Contract Manufacturing: Annual Commercial Demand
    • 14.3.2.1. Commercial Demand for Peptide API Contract Manufacturing: Analysis by Mechanism of Action
  • 14.3.3. Peptide API Contract Manufacturing: Analysis by Type of Peptide Synthesis Method
  • 14.3.4. Peptide API Contract Manufacturing: Analysis by Geographical Regions

15. CAPACITY ANALYSIS

• 15.1. Chapter Overview
• 15.2. Key Assumptions and Methodology
• 15.3. Peptide API Contract Manufacturing: Global Installed Capacity
  • 15.3.1. Analysis by Company Size
  • 15.3.2. Analysis by Scale of Operation
  • 15.3.3. Analysis by Geography
    • 15.3.3.1. Analysis of Peptide API Contract Manufacturing Capacity in North America
    • 15.3.3.2. Analysis of Peptide API Contract Manufacturing Capacity in Europe
    • 15.3.3.3. Analysis of Peptide API Contract Manufacturing Capacity in Asia-Pacific and Rest of the World
  • 15.3.4. Analysis by Company Size and Location of Manufacturing Facility
  • 15.3.5. Analysis by Chemical Synthesis Method Used
• 15.4. Concluding Remarks

16. LIKELY PARTNERS ANALYSIS

• 16.1. Chapter Overview
• 16.2. Assumptions and Key Parameters
• 16.3. Scope and Methodology
• 16.4. Potential Strategic Partners for Peptide API Contract Manufacturers in North America
• 16.5. Potential Strategic Partners for Peptide API Contract Manufacturers in Europe
• 16.6. Potential Strategic Partners for Peptide API Contract Manufacturers in Asia Pacific and Rest of the World
• 16.7. Spider-web Analysis: Potential Strategic Partners

17. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

• 17.1. Chapter Overview
• 17.2. Assumptions and Parameter Definitions
• 17.3. Make versus Buy Decision Making Framework
  • 17.3.1. Scenario 1
  • 17.3.2. Scenario 2
  • 17.3.3. Scenario 3
  • 17.3.4. Scenario 4
• 17.4. Concluding Remarks

18. TOTAL COST OF OWNERSHIP FOR PEPTIDE CONTRACT MANUFACTURING ORGANIZATIONS

• 18.1. Chapter Overview
• 18.2. Key Parameters
• 18.3. Assumptions and Methodology
• 18.4. Total Cost of Ownership for Peptide API Contract Manufacturing Organization, Y0-Y20
• 18.5. Total Cost of Ownership for Peptide API Contract Manufacturing Organization: Analysis by CAPEX and OPEX, Y0 and Y20
  • 18.5.1. Total Cost of Ownership for Peptide API Contract Manufacturing Organization: Analysis by CAPEX, Y0
  • 18.5.2. Total Cost of Ownership for Peptide API Contract Manufacturing Organization: Analysis by OPEX, Y1-Y20

19. GLOBAL PEPTIDE API CONTRACT MANUFACTURING MARKET

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Global Peptide API Contract Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.3.1. Scenario Analysis
    • 19.3.1.1. Conservative Scenario
    • 19.3.1.2. Optimistic Scenario
• 19.4. Key Market Segmentations

20. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY TYPE OF API

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Peptide API Contract Manufacturing Market: Distribution by Type of API
  • 20.3.1. Peptide API Contract Manufacturing Market for Generic APIs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 20.3.2. Peptide API Contract Manufacturing Market for New Chemical Entities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 20.4. Data Triangulation and Validation

21. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY TYPE OF PEPTIDE SYNTHESIS METHOD

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Peptide API Contract Manufacturing Market: Distribution by Type of Peptide Synthesis Method
  • 21.3.1. Peptide API Contract Manufacturing Market for Chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 21.3.2. Peptide API Contract Manufacturing Market for Non-chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 21.4. Data Triangulation and Validation

22. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY TYPE OF CHEMICAL SYNTHESIS METHOD

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Peptide API Contract Manufacturing Market: Distribution by Type of Chemical Synthesis Method
  • 22.3.1. Chemical Synthesis Market for Solid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.3.2. Chemical Synthesis Market for Liquid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.3.3. Chemical Synthesis Market for Hybrid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 22.4. Data Triangulation and Validation

23. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Peptide API Contract Manufacturing Market: Distribution by Scale of Operation
  • 23.3.1. Peptide API Contract Manufacturing Market for Commercial Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.2. Peptide API Contract Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 23.4. Data Triangulation and Validation

24. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. Peptide API Contract Manufacturing Market: Distribution by Company Size
  • 24.3.1. Peptide API Contract Manufacturing Market for Very Large and Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.2. Peptide API Contract Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.3. Peptide API Contract Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.4. Data Triangulation and Validation

25. PEPTIDE API CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY

• 25.1. Chapter Overview
• 25.2. Assumptions and Methodology
• 25.3. Peptide API Contract Manufacturing Market: Distribution by Geography
  • 25.3.1. Peptide API Contract Manufacturing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.1.1. Peptide API Contract Manufacturing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.1.2. Peptide API Contract Manufacturing Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.2. Peptide API Contract Manufacturing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.1. Peptide API Contract Manufacturing Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.2. Peptide API Contract Manufacturing Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.3. Peptide API Contract Manufacturing Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.4. Peptide API Contract Manufacturing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.5. Peptide API Contract Manufacturing Market in Ireland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.6. Peptide API Contract Manufacturing Market in the Netherlands, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.7. Peptide API Contract Manufacturing Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.8. Peptide API Contract Manufacturing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.9. Peptide API Contract Manufacturing Market in Sweden, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.10. Peptide API Contract Manufacturing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.3. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.3.1. Peptide API Contract Manufacturing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.3.2. Peptide API Contract Manufacturing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.3.3. Peptide API Contract Manufacturing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.3.4. Peptide API Contract Manufacturing Market in Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.3.5. Peptide API Contract Manufacturing Market in Other Countries, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.4. Market Movement Analysis
  • 25.4.1. Penetration-Growth (P-G) Matrix
• 25.5. Data Triangulation and Validation

MARKET OPPORTUNITY ANALYSIS WITHIN GEOGRAPHY

26. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 26.1. Peptide API Contract Manufacturing Market in North America: Distribution by Type of API
  • 26.1.1. Peptide API Contract Manufacturing Market in North America for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.1.2. Peptide API Contract Manufacturing Market in North America for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 26.2. Peptide API Contract Manufacturing Market in North America: Distribution by Type of Peptide Synthesis Method
  • 26.2.1. Peptide API Contract Manufacturing Market in North America for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.2.2. Peptide API Contract Manufacturing Market in North America for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 26.3. Peptide API Contract Manufacturing Market in North America: Distribution by Type of Chemical Synthesis Method
  • 26.3.1. Chemical Synthesis Market in North America for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.3.2. Chemical Synthesis Market in North America for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.3.3. Chemical Synthesis Market in North America for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 26.4. Peptide API Contract Manufacturing Market in North America: Distribution by Scale of Operation
  • 26.4.1. Peptide API Contract Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.4.2. Peptide API Contract Manufacturing Market in North America for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates
• 26.5. Peptide API Contract Manufacturing Market in North America: Distribution by Company Size
  • 26.5.1. Peptide API Contract Manufacturing Market in North America for Very Large and Large Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.5.2. Peptide API Contract Manufacturing Market in North America for Mid-sized Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.5.3. Peptide API Contract Manufacturing Market in North America for Small Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27. MARKET OPPORTUNITY ANALYSIS: EUROPE

• 27.1. Peptide API Contract Manufacturing Market in Europe: Distribution by Type of API
  • 27.1.1. Peptide API Contract Manufacturing Market in Europe for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.1.2. Peptide API Contract Manufacturing Market in Europe for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 27.2. Peptide API Contract Manufacturing Market in Europe: Distribution by Type of Peptide Synthesis Method
  • 27.2.1. Peptide API Contract Manufacturing Market in Europe for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.2.2. Peptide API Contract Manufacturing Market in Europe for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 27.3. Peptide API Contract Manufacturing Market in Europe: Distribution by Type of Chemical Synthesis Method
  • 27.3.1. Chemical Synthesis Market in Europe for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.3.2. Chemical Synthesis Market in Europe for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.3.3. Chemical Synthesis Market in Europe for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 27.4. Peptide API Contract Manufacturing Market in Europe: Distribution by Scale of Operation
  • 27.4.1. Peptide API Contract Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.4.2. Peptide API Contract Manufacturing Market in Europe for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates
• 27.5. Peptide API Contract Manufacturing Market in Europe: Distribution by Company Size
  • 27.5.1. Peptide API Contract Manufacturing Market in Europe for Very Large and Large Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.5.2. Peptide API Contract Manufacturing Market in Europe for Mid-sized Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.5.3. Peptide API Contract Manufacturing Market in Europe for Small Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD

• 28.1. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of API
  • 28.1.1. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.1.2. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 28.2. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Peptide Synthesis Method
  • 28.2.1. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.2.2. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 28.3. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Chemical Synthesis Method
  • 28.3.1. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.3.2. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.3.3. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 28.4. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Scale of Operation
  • 28.4.1. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.4.2.Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Preclinical/Clinical Scale, Historical Trends (since2021) and Forecasted Estimates
• 28.5. Peptide API Contract Manufacturing Marketin Asia-Pacific and Rest of the World: Distribution by Company Size
  • 28.5.1. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Very Largeand Large Companies, Historical Trends (since2021) and Forecasted Estimates (till2035)
  • 28.5.2. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Mid-sized Companies, Historical Trends (since2021) and Forecasted Estimates (till2035)
  • 28.5.3. Peptide API Contract Manufacturing Market in Asia-Pacific and Rest of the World for Small Companies, Historical Trends (since2021) and Forecasted Estimates (till2035)

29. SWOTANALYSIS

• 29.1. ChapterOverview
• 29.2. Strengths
• 29.3. Weaknesses
• 29.4. Opportunities
• 29.5. Threats
• 29.6. Comparison of SWOT Factors

30. ROOTS STRATEGIC RECOMMENDATIONS

31. INSIGHTS FROM PRIMARY RESEARCH

32. REPORT CONCLUSION

33. TABULATED DATA

34. LIST OF COMPANIES AND ORGANIZATIONS

35. CUSTOMIZATION OPPORTUNITIES

36. ROOTS SUBSCRIPTION SERVICES